<SEC-DOCUMENT>0001104659-26-029968.txt : 20260318
<SEC-HEADER>0001104659-26-029968.hdr.sgml : 20260318
<ACCEPTANCE-DATETIME>20260318085117
ACCESSION NUMBER:		0001104659-26-029968
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260318
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260318
DATE AS OF CHANGE:		20260318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gain Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819411
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851726310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40237
		FILM NUMBER:		26765825

	BUSINESS ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
		BUSINESS PHONE:		(301) 500-1556

	MAIL ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm269191d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:GANX="http://gaintherapeutics.com/20260318">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_GANX_gaintherapeutics.com_20260318 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20260318_20260318 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001819411 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000004" name="dei:EntityCentralIndexKey">0001819411</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ganx-20260318.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-03-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-18</xbrli:startDate>
        <xbrli:endDate>2026-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20260318__20260318_za4K2FqftW92"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):<b>
<span id="xdx_906_edei--DocumentPeriodEndDate_c20260318__20260318_z05jzdeCqAb6"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 18, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 25%">&#160;</td>
    <td style="width: 50%">&#160;</td>
    <td style="width: 25%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">	<b><span id="xdx_90C_edei--EntityRegistrantName_c20260318__20260318_zlsBJBHJzjze" style="font-size: 18pt"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000011" name="dei:EntityRegistrantName">Gain Therapeutics, Inc.</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">(Exact name of  registrant as specified in its charter)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 33%; padding-top: 3.75pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20260318__20260318_zwhbpORe7Uh5"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; padding-top: 3.75pt; text-align: center"><span id="xdx_904_edei--EntityFileNumber_c20260318__20260318_zOvJOVidU3he" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000013" name="dei:EntityFileNumber">001-40237</ix:nonNumeric></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; padding-top: 3.75pt; text-align: center"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20260318__20260318_zKnA84IfGMoj" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000014" name="dei:EntityTaxIdentificationNumber">85-1726410</ix:nonNumeric></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center">(State or Other Jurisdiction    <br/>
    of Incorporation)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">(Commission File<br/>
 Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer <br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_904_edei--EntityAddressAddressLine1_c20260318__20260318_zOKQ6LCkzh9g"><b><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000015" name="dei:EntityAddressAddressLine1">4800 Montgomery Lane</ix:nonNumeric></b></span><b>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20260318__20260318_ztBpMd7bPml8"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 220</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span></span></b><b> <span id="xdx_901_edei--EntityAddressCityOrTown_c20260318__20260318_zZ3QajSDTeo6"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000017" name="dei:EntityAddressCityOrTown">Bethesda</ix:nonNumeric></span></b><b>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20260318__20260318_zeXsj5c6dtl2"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></b> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20260318__20260318_zxs2xM1p7JEk"><b><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000019" name="dei:EntityAddressPostalZipCode">20814</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Address of principal executive offices, including zip code)</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <b>(<span style="text-decoration: underline"><span id="xdx_90C_edei--CityAreaCode_c20260318__20260318_zPw8UzVlfk24"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000020" name="dei:CityAreaCode">301</ix:nonNumeric></span></span></b><b>)
<span style="text-decoration: underline"><span id="xdx_90E_edei--LocalPhoneNumber_c20260318__20260318_z6gKxBM3hnt5"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000021" name="dei:LocalPhoneNumber">500-1556</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">N/A</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_90F_edei--WrittenCommunications_c20260318__20260318_zBjDLF4uYlz5" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_90E_edei--SolicitingMaterial_c20260318__20260318_zVrETUMiDaCe" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_906_edei--PreCommencementTenderOffer_c20260318__20260318_zBEZSbv2Vx29" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 96%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20260318__20260318_zLjMso0HEKDe" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Securities registered pursuant
to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 39%; padding-top: 3.75pt; text-align: center"><b>Title
    of Each Class:</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 20%; padding-top: 3.75pt; text-align: center"><b>Trading
    Symbol</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 39%; padding-top: 3.75pt; text-align: center"><b>Name
    of Each Exchange on which Registered</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90E_edei--Security12bTitle_c20260318__20260318_zGp5tgh95q87" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90F_edei--TradingSymbol_c20260318__20260318_z9v0GD4HnQ85" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-03-18" id="Fact000027" name="dei:TradingSymbol">GANX</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; text-align: center">The
    <span id="xdx_90B_edei--SecurityExchangeName_c20260318__20260318_zoSXDI9E0g0l" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span><span style="font-size: 10pt"> Stock
    Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR&#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Emerging growth company&#160;<span id="xdx_904_edei--EntityEmergingGrowthCompany_c20260318__20260318_zMQONmV2zm78" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span id="xdx_908_edei--EntityExTransitionPeriod_c20260318__20260318_zFk98OcLMDok" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-03-18" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>




<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01. Reguation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2026, Gain Therapeutics, Inc. (the &#8220;Company&#8221;)
issued a press release regarding the information described below in Item 8.01, which press release is attached hereto as Exhibit 99.1
and is incorporated by reference herein.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Current Report on Form 8-K under Item 7.01,
including the information contained in Exhibit 99.1, is being furnished to the SEC, and shall not be deemed to be &#8220;filed&#8221;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01. Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 18,
2026, the Company issued a press release announcing </span> the presentation of an oral presentation and poster at AD/PD &#8482; 2026
International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Disease and Related Neurological Disorders, being held March 17-21,
2026 in Copenhagen, Denmark. The oral presentation outlined new clinical and biomarker data from the Phase 1b clinical study of GT-02287
further supporting disease-modifying potential in both idiopathic and GBA1 Parkinson&#8217;s disease. The Company also presented a poster
outlining preclinical data&#160;from&#160;a&#160;structurally distinct&#160;chemical series&#160;of&#160;allosteric glucocerebrosidase
(GCase) modulators, which are ready for IND-enabling studies&#160;for the treatment of Parkinson&#8217;s disease (PD)&#160;and other neurological
disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>AD/PD Oral Presentation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The oral presentation, entitled,&#160;&#8220;An Open-Label Phase 1b
Study of GT-02287 in Parkinson&#8217;s Disease,&#8221; was delivered on-site by the Company&#8217;s Chief Medical Officer, Jonas Hannestad,
M.D., Ph.D. Data on safety, tolerability, biomarkers, and clinical scores from the completed Part 1 of the study was presented. Of the
19 participants who completed dosing in Part 1, 16 chose to continue in the ongoing nine-month extension (Part 2). A Data Monitoring Committee
meeting on March 5, 2026, concluded that the study should continue without any changes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously presented in January 2026, in all participants with elevated
baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), GluSph decreased substantially after 90 days of treatment
with GT-02287.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 10, 2026, of the 16 participants enrolled in the ongoing
nine-month extension, 14 had completed dosing for five months (Day 150). MDS-UPDRS scores remained stable over 150 days of dosing. Preliminary data (subject to quality assurance) suggests that participants
with elevated baseline levels of GluSph in CSF continued to benefit more than those with low baseline levels of GluSph in CSF, with a
difference of 6.7 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150. Additionally, in individuals
with high levels of CSF GluSph at baseline, levels of DOPA decarboxylase (DDC) decreased following 90 days of treatment with GT-02287.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>AD/PD Poster Presentation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The poster, titled, &#8220;Novel Allosteric GCase Modulators, Different
From the Clinical Stage GT-02287, for the Treatment of Parkinson&#8217;s Disease,&#8221; was presented on-site by the Company&#8217;s
Head of Research Ana Maria Garcia-Collazo, Ph.D. The new, orally available, brain penetrant chemical series &#8211; led by GT-04686 &#8211;
demonstrates potential for future clinical development, as evidenced by restoration of key biological activities that are impaired in
Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221;
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded
by words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;will,&#8221;
&#8220;may,&#8221; &#8220;should,&#8221; or similar expressions. These forward-looking statements reflect management&#8217;s current knowledge,
assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected
in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be
achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements.
Such statements include, but are not limited to, statements regarding: the development of the Company&#8217;s current or future product
candidates including GT-02287 and GT-04686; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for
GT-02287, including any extension studies; expectations regarding the completion and timing of results from a Phase 1b clinical study
for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; whether&#160;results&#160;from
preclinical studies and initial data from early clinical trials will be predictive of the final&#160;results&#160;of the clinical trials
or future trials; and the potential therapeutic and clinical benefits of the Company&#8217;s product candidates. For a further description
of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as
well as risks relating to the Company&#8217;s business in general, please refer to the Company&#8217;s Annual Report on Form 10-K for
the fiscal year ended December 31, 2024, under the heading &#8220;Risk Factors,&#8221; and other documents of the Company filed, or to
be filed, with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by this
cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of
this Current Report on Form 8-K. The Company has no obligation, and expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether because of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exhibits listed below are furnished as part of this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Exhibit No.</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Description</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><a href="tm269191d1_ex99-1.htm">99.1</a></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: left"><a href="tm269191d1_ex99-1.htm">Press Release, dated March 18, 2026.</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">104</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cover Page Interactive Data File (embedded within the Inline
XBRL document).</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Signature</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.35in">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.35in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt"><b>GAIN THERAPEUTICS, INC.</b></span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt; width: 50%">Dated: March 18, 2026</td>
<td style="font-size: 10pt; width: 5%"><span style="font-size: 10pt">By:</span></td>
<td style="border-bottom: black 1pt solid; font-size: 10pt; width: 45%"><span style="font-size: 10pt">/s/ Gene Mack</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td style="font-size: 10pt"/><td style="font-size: 10pt"><span style="font-size: 10pt">Gene Mack</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td style="font-size: 10pt"/><td>Chief Executive Officer &#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Okq3H8jLpCKyEInodskplnRHZjezR+otW5VoGBiGc75zhBiJLW10iQyXVZ7CCau6VA4hxxsymit6R7Lbx+BvjndtHSvj+vcHJuQZ9Mx8LOXVC7210RaLGMLFJIomcgbhMp5KyA4i6PSEzE0XaJxWJShTQMZUs0an+D0knFRLhqp3X3VGtppMDNE4HOQPyDCScKRGvYgfFtI0EcGon0BsmZ61d61bh6YjYV1i5evsQP83+AIIxUqQ -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm269191d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm269191d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gain Therapeutics Presents Additional Clinical
and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series&nbsp;at AD/PD 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Additional biomarker analysis reveals higher
CSF levels of DOPA decarboxylase (DDC &ndash; an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with
GT-02287 in individuals with high baseline CSF glucosylsphingosine</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Additional MDS-UPDRS data demonstrate continued
durability at day 150 of GT-02287 administration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Novel chemical series, headlined by advanced
lead GT-04686, is ready for IND-enabling studies for the treatment of Parkinson&rsquo;s disease and other neurological disorders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BETHESDA,
MD, March&nbsp;18, 2026</B></FONT> -- Gain Therapeutics,&nbsp;Inc. (Nasdaq: GANX) (&ldquo;Gain&rdquo;, or the &ldquo;Company&rdquo;),
a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies,
today announced the presentation of an oral presentation and poster at AD/PD&trade; 2026 International Conference on Alzheimer&rsquo;s
and Parkinson&rsquo;s Disease and Related Neurological Disorders, being held March&nbsp;17-21, 2026, in Copenhagen, Denmark. The oral
presentation outlined new clinical and biomarker data from the Phase 1b clinical study of GT-02287 further supporting disease-modifying
potential in both idiopathic and GBA1 Parkinson&rsquo;s disease. The Company also presented a poster outlining preclinical data&nbsp;from&nbsp;a&nbsp;structurally
distinct&nbsp;chemical series&nbsp;of&nbsp;allosteric glucocerebrosidase (GCase) modulators, which are ready for IND-enabling studies&nbsp;for
the treatment of Parkinson&rsquo;s disease (PD)&nbsp;and other neurological disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AD/PD Oral Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The oral presentation, entitled,&nbsp;&ldquo;An Open-Label Phase 1b
Study of GT-02287 in Parkinson&rsquo;s Disease,&rdquo; was delivered on-site by the Company&rsquo;s Chief Medical Officer, Jonas Hannestad,
M.D., Ph.D. Data on safety, tolerability, biomarkers, and clinical scores from the completed Part&nbsp;1 of the study support continued
development of GT-02287 for PD. Of the 19 participants who completed dosing in Part&nbsp;1, 16 chose to continue in the ongoing nine-month
extension (Part&nbsp;2), further supporting the tolerability of GT-02287. A Data Monitoring Committee meeting on March&nbsp;5, 2026, concluded
that the study should continue without any changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously presented in January&nbsp;2026, in all participants with
elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), GluSph decreased substantially after 90 days of
treatment with GT-02287. Elevated GluSph, a result of GCase dysfunction, has been shown to increase the aggregation of alpha synuclein
and to impair mitochondrial and lysosomal function in neurons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March&nbsp;10, 2026, of the 16 participants enrolled in the ongoing
nine-month extension, 14 had completed dosing for five months (Day 150). MDS-UPDRS scores remained stable over 150 days of dosing. Preliminary
data (subject to quality assurance) suggests that participants with elevated baseline levels of GluSph in CSF continued to benefit more
than those with low baseline levels of GluSph in CSF, with a difference of 6.7 points in the sum of MDS-UPDRS Part&nbsp;II and Part&nbsp;III
scores between the two groups at Day 150.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, in individuals with high levels of CSF GluSph at baseline,
levels of DOPA decarboxylase (DDC) decreased following 90 days of treatment with GT-02287. DDC is responsible for converting levodopa
into dopamine in the brain and peripheral nervous system and is elevated in the CSF of people with Parkinson&rsquo;s &ndash; likely due
to dopaminergic neuron dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gene Mack, President and CEO of Gain Therapeutics, commented on the
results, saying, &ldquo;We are encouraged by the evolving biomarker evidence in the Phase 1b clinical study of GT-02287 in Parkinson&rsquo;s
disease that suggests GT-02287 is targeting the causative biology of PD. Building on our previously reported reduction of GluSph in CSF,
this additional data shows a correlation between decreased levels of GluSph, decreased levels of DDC, and improvements in MDS-UPDRS scores
associated with treatment with GT-02287.&rdquo; He continued, &ldquo;Importantly, MDS-UPDRS scores remained stable and durable across
the overall study population after 150 days of treatment with GT-02287, which we view as an encouraging signal in this progressive neurological
disorder. The totality of the data continues to support the potential of GT-02287 in both idiopathic and GBA1 Parkinson&rsquo;s disease
and we hope to one day shift the treatment paradigm away from symptomatic relief and to disease modification.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jonas Hannestad, Chief Medical Officer of Gain Therapeutics, stated,
&ldquo;We are continuing to follow patients in the Phase 1b nine-month extension study that is expected to complete in September&nbsp;2026
and look forward to presenting further data at scientific conferences throughout the balance of the year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>AD/PD Poster Presentation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The poster, titled, &ldquo;Novel Allosteric GCase Modulators, Different
From the Clinical Stage GT-02287, for the Treatment of Parkinson&rsquo;s Disease,&rdquo; was presented on-site by the Company&rsquo;s
Head of Research Ana Maria Garcia-Collazo, Ph.D. The new, orally available, brain penetrant chemical series &ndash; led by GT-04686 &ndash;
demonstrates potential for future clinical development, as evidenced by restoration of key biological activities that are impaired in
Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These findings together support advancement of this novel chemical
series towards the clinic and the potential to be developed for PD and other indications where GCase deficiency is implicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Our proprietary Magellan&trade; drug discovery platform has
yielded novel GCase allosteric modulators that have generated promising preclinical data in Parkinson&rsquo;s disease models. We look
forward to further development of these novel, structurally distinct compounds and continued deployment of Magellan&trade; to identify
leads targeting other neurodegenerative and rare diseases,&rdquo; said Joanne Taylor, Ph.D., Senior Vice President of Research at Gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
PDF of the poster presented at AD/PD 2026 is available on the Science and Technology section of the Company&rsquo;s website at&nbsp;<U>https://gaintherapeutics.com/science-and-technology/posters</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About GT-02287</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain Therapeutics&rsquo; lead drug candidate, GT-02287, is in clinical
development for the treatment of Parkinson&rsquo;s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant
small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes
misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related
stress factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In preclinical models of PD, GT-02287 restored GCase enzymatic function,
reduced ER stress, lysosomal and mitochondrial pathology, aggregated &alpha;-synuclein, neuroinflammation and neuronal death, as well
as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD,
GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as
nesting. Compelling data in these models, demonstrating a disease-modifying effect of GT-02287, suggest that the drug candidate may have
the potential to slow or stop the progression of Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated
favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with an increase
in GCase activity among those receiving GT-02287 at clinically relevant doses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GT-02287 is currently being evaluated in a Phase 1b clinical trial
for the treatment of Parkinson&rsquo;s disease with or without a GBA1 mutation. The primary endpoint of the trial, which enrolled participants
across seven sites in Australia, is to evaluate the safety and tolerability of GT-02287 after three months of dosing in people with Parkinson&rsquo;s
disease. The recently commenced Phase 1b study extension allows participants to continue to be treated with GT-02287 for up to a total
of 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Initial results from the Phase 1b clinical trial in people with Parkinson&rsquo;s
disease demonstrated central nervous system target engagement, a reduction to baseline levels in the prespecified endpoint glucosylsphingosine
(GluSph), and improvement or stabilization in MDS-UPDRS scores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain&rsquo;s lead program in Parkinson&rsquo;s disease has been awarded
funding support early in its development from The Michael J. Fox Foundation for Parkinson&rsquo;s Research (MJFF) and The Silverstein
Foundation for Parkinson&rsquo;s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon
2020 research and Innosuisse &ndash; Swiss Innovation Agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Gain Therapeutics,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>Gain Therapeutics,&nbsp;Inc. is a clinical-stage biotechnology company leading the discovery and
development of next generation allosteric therapies. Gain&rsquo;s lead drug candidate, GT-02287 is currently being evaluated for the
treatment of Parkinson&rsquo;s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in
Gaucher&rsquo;s disease, dementia with Lewy bodies, and Alzheimer&rsquo;s disease. Gain has multiple undisclosed preclinical assets targeting
lysosomal storage disorders, metabolic diseases, and solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain&rsquo;s unique approach enables the discovery of novel, allosteric
small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan&trade; platform, Gain is
accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including
neurodegenerative diseases, rare genetic disorders and oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>This release contains &ldquo;forward-looking statements&rdquo; made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as &ldquo;believes,&rdquo; &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; or similar expressions.
These forward-looking statements reflect management&rsquo;s current knowledge, assumptions, judgment and expectations regarding future
performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could
differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited
to, statements regarding: the development of the Company&rsquo;s current or future product candidates including GT-02287 and GT-04686;
expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies;
expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies;
the timing of any submissions to the FDA or other regulatory bodies and agencies and the timing of any responses from the FDA or other
regulatory bodies and agencies; the timing of the commencement of any Phase 2 clinical studies for GT-02287; and the potential therapeutic
and clinical benefits of the Company&rsquo;s product candidates, including GT-02287 and GT-04686. For a further description of the risks
and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks
relating to the Company&rsquo;s business in general, please refer to the Company&rsquo;s Form&nbsp;10-K for the year ended December&nbsp;31,
2024, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary
notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.
We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether
because of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain Therapeutics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apaar Jammu&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director,&nbsp;Investor Relations and Public Relations&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ajammu@gaintherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chuck Padala&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>chuck@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nic
Johnson and Elio Ambrosio</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>nic.johnson@russopartnersllc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>elio.ambrosio@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(760) 846-9256</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ganx-20260318.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaiDObOdzZR+OYkxtmB/belqvyIhxo/Q/y0AmN2mAZQH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:GANX="http://gaintherapeutics.com/20260318" elementFormDefault="qualified" targetNamespace="http://gaintherapeutics.com/20260318">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gaintherapeutics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20260318_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20260318_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ganx-20260318_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ganx-20260318_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ganx-20260318.xsd#Cover" roleURI="http://gaintherapeutics.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gaintherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm269191d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm269191d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y '$# 2(  A$! Q$!_\0
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M7<.F:5X6<QR"^B^'NBVMM8:U902.?#6A6MC?7ZVUO<QR-_8I_P $[?VB+/\
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MS\4_!W@?XG_L _M@?LW>%_BQX=UOQ+\'/B[\1;'X7^,?"^HZ+H&DVFN3:?\
M&RS^$?Q ^(FH?LR^+M>T34=,N?#OAGXU:7X6G\2:[)>>"H9QXX\-RZ.W$?!;
M_@I'K_[0OQ%,7P=_8A_:1\<?LR7'QC\=_!'3_P!KS1?$'[/">")_&G@#QWX@
M^&GCSQ.?A1J7QEL_C19?#'2_%?AW7H8?&$O@&]NKV&VO-0NO#MLRSHX,_3'R
M[_T/_@.W_P RM%7/M.H_\\]&_P#!T?\ Y044 ?!7_!1_]G;XH_M&^$OV4=)^
M%FCZ=K%]\)_^"@_[$W[0_C"._P!:L]"-E\-_@=\;-%\=^/-6M+B^>.#4=2TS
MP_I]U-I&A@R3:I?O'!%$[[5;SW_@H#^Q!=_MC_'7_@GY+XA\'2^+_@3\%?C/
M\=O&7QUL+/QYK7@#6[+0O%_[,_Q2\#^#;S0=6\->)/"?BJ]NKSXE>)O#%OJ5
MOX?UN,0Z%/JL<\'V:&Y-?JQ10!^%GP8_X)J:_P#LY_&?_@JY<?!KP)'X=^#_
M .U'^RK^SGX"^!-IJOQ)UWQW=ZG\4_ ?@3]J?2?'$.KW/Q#\4>)O$_AVRT_5
M?BGX,M-*^UZFN@75KJ%U-9@R:;J4B4O^"0O[,GQ>_9,\!?"3X2>//V#M9^ ?
MB3PK^SA\./AQ\3?C\/VI?"GQBT#QWXW^&OA_PSI$S:?\.-%\7W5UH>G>+=3M
MO$'B"+['I-E::+;-8Z.)I680P_O!10!_+1^RM_P1]_:,_9[\)_\ !+7QEXMU
MGXD?%ZY_9Q^+>L:U^T!^Q[\1?VD/%?BSX!_#F\\5W7C&V^'GQ\^ GAZ?Q O@
M&U\>_LTZMJNE:[H/AO4].\4:?J>@^+O'.K^'-1\-?$#PEX0N=3]N_:1_X)3_
M +3O[<?Q2_;V^)OC[]HWQQ^S3:?%71/AU^SS^SI\/_!VA? ;QS97_P $OV?;
M6Q^)WPM\<>-/B/XN^%WQ$^*?PSU?7/VI?$7CGXBL/@UXN\#^/?#"Z)X+\22Z
MSJFNZ1X:G\/_ -%-% 'X2_&3]B7]J/\ ;'^+7_!*SXK?&6_^*/P&U?X)?L\?
MM.V?[5GB#X"?'JT^''CSP3\<?BOX2_9FL],\/^!-<\"W(L_$_@W5?$OPY^(>
MGO/I6G1:(?#ZZ9JE_:Z==ZI]F7'_ &_?^";5S)^R_P#L(? +]E+]GV^^-'P]
M_9D_;A\,_M >//AAK/QA'@7Q9\0/"UY\,OVFH/B-XIUKXN>+/$VEZI=^.O&O
MQ3^-$?BSQ-J4EY'J.H:UK6N7:0PV92,?OE10!^'/CS]C7XI?M!?\$XOC/^R[
MX#_9QM_V)O'G_";^!/'GP8\)?$OXU6OQ\\)ZSXT^"WQ7^'/[0W@RZ\8^,O#&
MH^+M;T#X?>)/B%\/].\":O:6<FK^(]*\,W^O:SH'AQY9XIINU\$?#?\ ;4_:
M?_;-_9?_ &C?VD_V=/#O[*/PY_8U\)?&Z7P]X,C^-_@WX[^,OBU\:_COX8TK
MX9_\)!HMWX)\.Z+I?A3X3_#/X=IXS9+SQ%XAM/&?C74_%EC;W7PYTV;1DU.]
M_9&B@#\\I_@!\2)O^"G7AW]J#^Q[/_A4%C^P1X@^ 3:R^J1MJ=E\0=;_ &AO
M!?Q CT.'PV@AU273;OPIIEV9==N;2WAL)=-ACN0L\DC2_)_Q._X)S_%+X\0?
M\%D_ OB'6K?X;Z5^W#\5/@GXU_9^^(,%_P#VO+8ZO\&_V6OV<?"OA3Q!XLT3
M1YEOK?0-%^-_P:NH]4T.6ZT/5=5\*Z<JV%Z8_$<;']O:* /S4^!/Q3_X*7^/
MOB7\/=#^-_[('P/^ /P]\-V?B1_CI\18/VA)/BE-\0=<7P]=0^$;/]FOPAX9
M\/P:CHGA[4?%5UI][XTUSXUQ>'M3LM%LM<TG1/#>M7QT#QG<_EEXC_82_:_U
M;]JKPA\3_@;^QEX5_8<^+]W^U?X)^)'QR_:]_9T_;B\6Z5\ OC9\"-/^(>G:
MI\7M*^)?[(5EHNAV?Q*^)'QH\!Z-;6/B'1?$/PTTY+GXE67AWQA>_'NYTF'4
=9D_IXHH P?LNM_\ /SH__@BF_P#FBHK>HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 18, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 18,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gain Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1726410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4800 Montgomery Lane<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bethesda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-1556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GANX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm269191d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gaintherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ganx-20260318.xsd</File>
    <File>ganx-20260318_lab.xml</File>
    <File>ganx-20260318_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm269191d1_8k.htm">tm269191d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm269191d1_8k.htm": {
   "nsprefix": "GANX",
   "nsuri": "http://gaintherapeutics.com/20260318",
   "dts": {
    "schema": {
     "local": [
      "ganx-20260318.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ganx-20260318_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ganx-20260318_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm269191d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://gaintherapeutics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm269191d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm269191d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gaintherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-26-029968-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-029968-xbrl.zip
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MEZ4WK5>$'.']:K6&'Z]Z_03GI,!FS"A_7@6O'1T=X60WAQ:0\4"R7+J.[?:
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M<X. SE4O=]I4/6X5!='[7<YT$BHM:HL=8[%@:1(E>4+7OXJ33YY@6ZML(E=
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M5"]#S0K02CXC5E6!?I>5H*(6V^^7-S==BT]BL]HD_EKAC(@M_P502P,$%
M  @ :$9R7&BFERUA!P  Y%<  !4   !G86YX+3(P,C8P,S$X7W!R92YX;6S-
MG-]SVC@0Q]]OYOX''_<,!'+I-32Y3D)#AVG:Y$+:WMU+1]@"-)$E1I(#_/<G
MV4#Y8<F;%V_RD!"SDO;[65GV6I(OWB]3'CU3I9D4EXU.ZZ0141'+A(GI9>/K
MJ'DUZ@^'C4@;(A+"I:"7#2$;[__Z]9?(_ES\UFQ& T9YTHL^R+@Y%!/Y+OI"
M4MJ+/E)!%3%2O8N^$9ZY(W+ .%517Z9S3@VU7Q0-]Z(WK3,2-9N :K]1D4CU
M]6&XK79FS%SWVNW%8M$2\IDLI'K2K5BFL I'AIA,;VL[69ZL?XKB%YR)IY[[
M-2::1A:7T+VE9I<-U^ZZV<5I2ZIINWMRTFG_\_EV%,]H2II,.&PQ;6Q*N5K*
MRG7.S\_;^;<;TR/+Y5CQ31NG[8T[VYKMMRQ@O^.)9CV=NW<K8V+RJ%<V$WDM
MW'_-C5G3'6IVNLW33FNID\8&?DY024X?Z"3*9?;,:FY[DF:N(S36QV:*3BX;
M4R*6MJ+NFY/3SEM7S>]]:?MG(W(5V+!OW9T2)LS,=K$YS0R+\XBWG5%[7:"]
MU_Y<44V%R27?V@-[CM"EL=V*)AM77#7PAM8U,>,*K3M/)VJZGI:EMDW[L;!<
M.[1QB<MXSPON(B+5/H]-[\ZY:QJWIO*YG5!F^7?/W <'ZRP'9?_YD3=T-=9&
MD=AL:N)D3'E>_P]K<V#2KL&K#8E'6V.Y4_L6AS[M!N]*Q9%4"566]:8NHN*]
MD!UWU+5%>TZ4K:@9SQC?1GNB9.JCLR8A/8[N@K)-U$/SRK:?.!\&G$S+<1Z8
M 'EV,("6JL$B^H'J6+&YXU(!=L\2R+>+RK=$6\V8-^?. YTRYZ]SQ5U^J3L8
M'A<\18#@3S%'BJ!:I A<"9$1_D#G4E6 W[<$\OX#DW>9-B3,?V=$&:KX"D+Z
MR!@(^PP3MD<A$N]'181FC@\$^+$UD/@;U!L/CT8DY*,9Y=QE=$2 >GF9/1#[
MGYC8_3I? ?B;9W=]MY<6./N=(D#\;U\+_B.U2!&XIXK)Q%[2%8#]D3&0^CDF
M=8]"5-XW(H'2WIJ"\Q]\V ?RD% /F(X)+SP:V&,ZC+O$'(H<)>>LE(F*_5]*
M%!CZCC$4.4H:6B&Q9N#]3*D]9X*CBM\:BAPE :T263/S&V&86;DI@"]9.O[Y
MX'2?];$5E#%*TND3A<)V\Z1!&#>U$>)[: EEC))KAL2A<.Y;/8KPH4CH\A-=
MA4 ?F4))H^2807DHJ.\52XE:C5A</6@<VT)AHV2688$HM!_)<IA856S"BLG!
M:NC>(E#V*&DE2"Y*"(8BEFHN=QX7]V5FS\=57R;!(;VB(#0<*/GF"Z2C!.4J
M22PNO?YSRP3MA$)1:@Z>(\(+0$#F*\'>?1GV+AP[2AY:*?.58#]]&?93.':4
M7+12)B;VOOUXIQ[EPC,#[36&(D?)12LD8@+/KS1WZE[)9U:LD:JB?E0"BAXQ
M10V+1>WPQ44>TMLWEE#>B.EJN3A,SO=2&\+_8_.J.\ER>RASQ,0U)+3N!XQ%
MW-U#"]]2H@,3*%^47+543MU(7805)?[NNV\!!8J2@):)J9GGK71S'S,I@L]C
MCZV@7%$R29^HN@=>MZ!8>T_]G:_!*]A0AM5#&35C_*Z8L1[T99IF8OV,QC,K
MYC&%XD5)_X+R:D8]DIS%S# Q_6SO$!4CO)QSF1T4,DJRYQ=6,^%[15VDJ;WM
MSM=QN1T'ZFXR\8V\(7LH<91<KUHH+OFAUAE5+^5?4@H:!92T#RJZ[G&&QID=
M]E:=[OC1[9CQC#)'5E#6*"F?3U3-;+_(1T7<UKW1*AU+[M\>4FH()8R2X 6D
MU0QYSX]RO <F4+ HF5VI'*0QX689SXB84O_JA7)+*&"43"\D#FWLG8+&WND+
MQUZ4C,\G"HEML3;<GE%W8\ZFQ+^3+%@ O,\&DWA :MW[]_(M/VY7MTIS/P;V
M0SEVCRD4.,X6R9"\NE%G"3,T*5P:,$%$;%.J[;XV3W9>70H: )P]E$#1*(_W
MOU/./PFY$"-*M!0T*6[U0T_XO46@44"<0ZR0BQ*";Y)GEI+*%X(JSSG@,84B
M1YP[],C#67M9+&K>7GN*UW>$B/M*0,$C3B*&Q2*M3S/4^<R>Z0=BR-K#$']?
M"2A_Q G%L%BT]?.J;R\\4QF>,S\PA-)&7 I;*@T%\B@EG%]GF@FJ@V/+@2$4
M,N*:UU)I*)!O4JJF=E#[J.3"S-9[.T.P/06@T!%7M@:EXL!?_MQ'7NQ_"Y(O
ML0:_G0 1NU<DUFLWXM@MI"BNY"(ARD,]9 _ECKJQTB^T9O)W[LU=N_=/N3-#
MF[>%%CU4EX)& 25=A8K&N;;N[.0/7EKW[*"\$1/3,F$X>Z:R,6?Q@$L2O"_?
M,X/R1<Q"2V2AX+TFXDEE<Q.O[I6,*773)WI[M@$2(F %T) @YJ<O0H'SN$"F
MJ=M,)..GT<R*UG>9R5]F:OT+/C0(EH.&!G,3)T XTEV0_KG1BR;7JP<ZH<HM
M4WBD2W-M&WH*WQ0!BD/C@_I&(3"&DC!=M(]TW=H#[GVUQ3?NEWLGJSWR/U!+
M P04    " !H1G)<4<V*RSD<   JA0  $0   '1M,C8Y,3DQ9#%?.&LN:'1M
M[5WI5]M*LO_\_%?T>-Z="^=ZD3>P"?$<8QOBA"V8+#=?.&VI;3?(DJ(%;/[Z
M5]7=DB5;-I@ 2>9-SLP%I%9W574MOZKNEO;_/9V8Y):Y'K>MMW^6"MJ?A%FZ
M;7!K]/;/5K_=Z_WY[V9F?^Q#,VAJ>6^S8]]W]HK%N[N[PEVE8+NC8JG1:!2G
MV"8K&^U-4]N5-:U4_'IRW-?';$+SW/)\:NDL>LCDULWJ_O%NU'3@FCS1%*^$
M@U2*2UW#76/^0+SQ3E'>3#3U4YO69%,_;,H]NUHN[:ZC0[:('IBN:EM"FH%#
M]O7@XGC>W$]O/V]:]%UJ>4/;G5 ?IA![JN6U<KZ\$^LD[S$]T1'\71C9MP_V
M4\]72F$_2Y.3Y!1O#Z@72=Q@"^(.QX0;\$2Y%C8,O/R(4B=J/*3>0'2K;BPV
M=FV3>:FMQ9U$<]T.+-^=I1.B;B8>\%Q_N6NXF&ATU#K]&K4:46[Y8^92AP4^
MU[V";D^P]8Y6*=6S:#J,&LT,P7_[/O=-UMPORI^9_0GS*<&.\NQ[P&_?9MNV
MY3/+SU_.')"D+O]ZF_79U"\*^RK"4T79Y?X_\GERR)EI[)$^\]^04SIA>V1J
M3-^07D?\<J65NU>?^G^4.T>MUCG\0#9(/O_(ARNU*^3U*HW'JY#'QW=7[48/
M/>'I6N.*@>X $_"_UH19!OS?/S3IZ&I(38]MT),6ZZEKP63,VM"52\V>9;#I
M!S:[TL!3U4N-:JGT^&YW#D#4G:O2E3)ZV3]<VJ"+\E5_3%WF796OA(N3?7CB
MV@;==)"2<]5598F@57T/;&-&/']FLK?9(>C>'BEICD\N^01:G+([<F%/J)63
M%W(POLN'J.(&OPT?,[CGF'2V1RS;8GB/3_=079D+-B#^X(;!+#0(_ M:G083
MZ$>7RC[U+]CP;;;EG0U10_):)0]61+CQ-GM(=5_#?Y4LL8!I&(OQO80B9)M"
M$_:+B9Y_9*QJ?*Q45<DVY[J2-G QSC.2X;(A<R'&,D_<1[^YYXF ".00$>7V
MQBY2-J+6-!\:2F'J&5EUVP?O\#;K\8EC,O0(:IA$SW(HSPY<-1(T$M.^IY@7
MC"XPK_Q4V)()AL.+T65NX(TA9RX1A+/4V-+N?4C*9O'A:+!BVFAJ+ <$:1M+
M)$!T=_T.]5ES3GW8S_S>XE.@*BN>">\LD!0?/;RFQ)<0:6!Q*4\PKD4A3ACU
M I<UE1'N09.PJ_!6HG_L*[US:<^K^E?,BS9/'&#N-!8' 0N'B5L2*#XIE)WZ
MMCN_NS'OB^2E]!D;L<,L>\*M!\9\4!Z+@Z9T&]Z.L[\H1F5Z<TN3)J]\WGX1
MGFUF,IE])W21$^J.N+5'M"P@ 0?NQ7WZ16"R_#D=B7 6=ZSRJ;QO.^"5RPYX
M?G5E8/N^/=DC%;QVQPU_C&Y;^R.;>'Q@NT"/?/S I/H-@3Z(9YO<>$/4S; G
M>;\TOX^Q(._Q>P@T<#7;_-<_2SO:&\F:^F^,A6*"AU3.DUUJ\3Z=Q!./C4*A
M-*!O: K]HXGFJ<E'<$D'S\)<D,>@^>FT=]GMD/YEZ[+;WR\.FB\]8+_;_G31
MN^QU^Z1UVB'=K^UWK=.C+FF?G9ST^OW>V>EK4/&%>F/(Z'P;GN\4V@52UFK5
MQHN/_*-SNMQGI/5"D;44,Q#*M.\YU(J/%ZI:7=P=- _/+DXRLA4Z/D1-#:TC
M8&$^W['U "$%@O K/8*L<_!Z3ZL?RH??A_Z71AFZ>R*V:,2Q17S,;+.>_["(
M)?:+2&U3SIGZU4DZEE]J[AZGF& <%]W32W+1/3^[N'P-4PCY>OF1S@/7"ZCE
M$]^&!W5,JTFI0FR7E&I;QC:QAP22J@S<"ESN<QBP.]7'U *_V=)]O%UJ5*H1
MI;_O/".R0G8NF&.[/MD*_V84XBCS?,)NH25QQ6UF;.^!\):,<V?!.,\%-.M*
MW)9NI5KM^MY@[>^MP<Y&5BJK(&^S?.KO&=#[!-J.#3J; <',2EIQ24NSX@1Q
MV>8)=?4Q.)\<P6'66O9+JJ3LW*<#D\%%TX1A=:SS98$'_-NAAA'^O3$!,>01
M 0K=-DWJ>.!XP]\$KMSWW;#_6^;Z7*=F2*OTX@I][OM&V$[U7J[],==8WUC5
MK*8]JMEB;_ ?=U/Z@#&<O;?92B2S--G_#ZCTHD:WE4;+M/*"C;B'13@?,_IT
MA3:]@_<'[][?7]^S[.KH]K1P5"HMI[I)FK+-(\HM<ADK!.5(S](+:Q7Z<7*%
M<+ZY4+>Z4R!>4(WN!!Q(2"ZA'O$<IF.>:1 @FOL> =\*[L7=3M)4%/;P8NXU
M+>+\EA;X4(Z@1J]48'#%A@1IE<)N#7%:JG16X31-X;1%FZDF; :4SW8A:(B2
M==\'7]N6-=VV;:PPH;OQP#F[8+N?QK6GQ@2LIF.1P6>.:]^B]BT%A?*R+:VE
M%6(D,^D=A)?'P+X4CQ9*/)R>4CP97.\,'SNQY<TG=M6\'7*3 8,#YJ9/TMGM
M^[//W/A4&:?[N4@[GNCJ*LO3,R<)BU:E?%4K5W:7)^.GS\(3S&M5Q+FDTYXJ
MQNE"*]=-R0>K5:_VAD<G]O6+3$E*H74%?9 =U?*EW?).M:0]-$&QR+,D\900
M-!=M-(.%E<+=$D:,</X,UT;(>T#QGL$ESL>A!FY1#@JQ*6']VZD:L,H1KU&:
M'V5AO?O=:MN3"?=P99B@>2B&Y"QLK[.#7X^57N&BT"^0[L0Q[1E,UGQRDBI&
M3NW"=JH&/1M.^.EED55>N648+O,\]>.86ZRTPCU_^+ASW+ZY'S=&/V3SM66;
M3Z$AVZS6-8V<0*\C&T:8D6-JI<3)N>4/FCFRR&KK 5;+Z:SZ!\Z)L3LXGYCU
MIR/KG<?P6<XV^P$'AU(NI[BU9\@0GZXU"H8ER!@TET1<2A-Q&WX]<R_M.RM=
MP-\J'^EUOW/)[,UR](2 =U<*>#Y\MGG P$][!ETGW335::3Q)9S_F7L.")!;
M^@JPR;YZUS5]Q_#-S<J$FX'-^DKN%X@4A8B922UCC0B6V-])8__<!IK,;]Q9
MC;2G7GEZ4G)VWW=O?LA+-%:RER BVRQK]5)U+2)X==/94I0B!'!<F /N4).P
M*=,A?;[%K!4"#PX$M\P 8QVYYP[(QF#;JKS[PG6_P<O7G2#8-K<2\5FT,IBN
M\- >"2P O[@5:35F14MNN8RN5KCSN_JG^\_F\*9<?;(K*2?*>?$QL\V*MK3
M'VE6W(-L9Y[,;%<Q>VP#%#H?V];:-&EG]&%Z<%(96_YFN6R"X4399W'<;+.F
M:?E2K;:Z:/DZM<NM>2GJ7_^LETN[;SQH9S(':266(#9N19!)T[@9_;[%\Z@(
M\@AU.BVV7FU"#B%& 9"6Q3=7A"SXDTI_!U,Q)'(M Q ^QIZ,2;VPQ/_;SLEU
MX$&J,,LVVV,&Z3G "4(=B,O@VC$5'-A3,F"F?8?<XTV4$:GG/Y A-U$KN0<J
MZC.8, ,7A3P^"4P?P*P=>.:,>#"AWG FGE0/V ,86"8F<K4H7N,4$Y^AUBR\
M-[1-&!R?0ZS ,7'S]EY]/6U>W8Q7,Q>KG4^D1L7;Y6@;54@:.[CS86VE><6D
M9I97"+1"N<:M9'N3#5-2J4/EN;^XW(<9QM0YL%12Z:6[[X/KSO%A-?C;O*\E
M2RI#.N'F;(]\ 6&A +TGKUX-;-MDU!*[XA;\?J)$F4JU-*7ZFY6N']/CN<A2
M9:HZCNW2>?B?GJ"".+%E5-Q90JKEFM1]H?2QY5-<-=TJ[9+VX04I5[0"-%2E
M%I'%1RG\THZ4E5JUX$W^?ZIV"$KZMLEUD+0U.@%O!R[/3-?KSV[W\M,)[] V
M^PEZG:CM+I/\'$H][W4CO9XH$I8UNE2E^5(YIM2)C0"12E>U@FSY7ZW^<:T.
MT]ISEZ';PVVS8O\-1F?W;#A<!;H/NM_Z@]ORYVFY\1.T.U$F7TWZ<V@Y])[7
M8]T_JP\O58U\>6NP_3B=EVW_J_4_KO5:NM;W/"]@[H.Z?WQ]XMG:N^Z'SL_P
M[+4UNK_$P*]O 166KV[IC[, U?8A"WAI;/\C8ZVME*6I;@S8R:2'N9 VA7+,
MQ#?5"4^BDB"0W0_G/!O3^JK["O_C=Y*,N<_RR!##8T1W+G7FZ]^-C=:_!\U+
M/&D7KL)VJ3XF;9-ZF!8/7G\-?PUC96U3QEQJA BT/YL,;/-78VGCN<)-9HFI
MBAPB&#F,!%<N(D^PR>ZRE;L*TZA/4%Q6%&^\$IV2/DE_-BN5!T(ITT/LD5/S
M1^-&[7M]=\T^BR?6>A,+D8OT9)L84$'2?=_6;W+ LDMNJ1DP\K]: 1=BB(,'
MOL;K-BG%-&CM_LO7D'M8D5&&(FTD7>B-6^VH4WUG?:S7GE_HB<7)!#'9)IZN
M_26%>3F6EK@HU(,%90XM=/6>5;O_M=-K=+619CZ+;!?71AE0D+8L6JZG*7N<
MWBPX',^@WU=-P-H=)=)*A(Q.J'O#?')\W'ZAC2,;PY'G*8%O,&P$F7N6@9"7
MD<&,Z*)(#H_>@/-F8H_40@6;>P1$#-@:>Q^1D6O?^6-$S@Y6M:E'##;DEMS!
M*TM_6BW$>0MU/WE:HA+"9I3 [AM1!-1JVQG;5:"[/,B74WI(.W@1(7#5%^)P
M?'R[\.KP\M7G4P[;39\81<W:O43AHT?BR;9\,-U!G'P\.YU\+M]/=NLOG%3Z
M;K"84Z9L+D@E/=N<KO33OZ4RK%_?Z@W7&&8NP].MG"\M48W!AID):1K8L&6+
MY#?PF&@%PZJ%,'SQ"!>)G#QNC5,GQC)G./@=AZ'1'UC $=QQV2WWF)$!ST M
M'>NI5!>O\L#&^-87@[J&)Y? C%C&F#R&M46CC#%N_(5TY:XGE7MZ&=$L3_JD
M:_;A3:-^IA^?=.R;UR^75+04U5XB_,$RR0\=/'N./#KSA//1E901Y9GI#<Y'
MQ[*<U"PH=G[ZN<Y'O\1QKQ?M/,85\O,&>O@>8+D,!A+,"0RY+.:5^>2#I]QW
M!%Q</E&>/$*N3MTOC>XR>I,?,+ @H- 1%,='W%FA-QN.&)_KYYCF7S)$@*GV
M?#8ANP6M5,"\/)#[% X[I,,]W;3Q10N%%ZN'Q>EXX=);--2919(G.7-DQ8DX
MLH6!!7<JE;4W[1 VP5^E-]L9CK5J@U (4;@UT(4 23T1-B%P81##9[D5O8L+
M4+"GNWP SZC=)181HJ^#Z'.J,)+L"X&U[U.(S08!XAB$/HHH=\P'W">-1J&4
M@3@I]Z.$!Q.P^QF)WB$CGN-6X5EUZ754\W)!?B O?PR\M@/7Q8/&ZAPR*FNX
M04<6X2.%1H@3;B5;G T,S33,2N(BS:$\!PR?&0:NQ;VQW.8C<HUN.T=0Y-Z8
MFJ; 0@,&$PL02[091-HRY"8SE*YD$ GAXX!A'-MC8A]IA&'JCTQD<CCW="+1
M5EPQXXU#[<PAQ+(Q6;L#E$6\8' -XV44&R:G V[*H<3@%#RWI.<A]E8K&K=0
M/0'@J4U/*_=VV,,,YGAQ?@2YBR N!^!29XX\!2H(&B#>%":"^ZP@60?! JH$
M,FAX3E1/4 2,@U%)@GXXWUNOK:_IK.O"6<OS2ET\=.\]IX=^)5Z6ZC(AG'[@
M/65Q]YV1[ALU1[EGLL(M4\N"Y +75H@"Q=(BH1'(+]J;!R2!;IO)ZV@18+<^
M;HST2:M3/.^@[57KY3<B?F1ZB*8LT1B>;=M6J('P<,N\'S-@P(TVO&)WYY!H
M<<NSK>@J1%M%J &>S13V=<H"US;M$1;!L8% 72 )Z9W& $U"4>SFRR4I#=3Z
MMNTP:PR0!=\3PRS,Z@H8WE)XLP/?%%X0TS(=?A5C(1$#;N.#P+1!?4J&KCT1
M(CL?(YFEP;RUYP>&V+UX=)G7RN7Z;@8<IU!.+W#01R.UAN0O/[$-F'^QN]'&
MMR)BY@<D Q0:0^+#;8>"D]<%!4<'K5**I%1/DJ-PVB%SLD/.Y/2+"<M(_N1F
M2A91C!Q))4>VY&_J J2\@>X'("CP,3 4$(]N%6_A2](DPZ")S),7[:%ZW#3%
MB$#[R QT6P<5&+BVQPV@-;-UU(8?VP2X#TQ\-9471GSJ(F:@($",$KW33IY9
M=&#*+!A"5SA.&$-\:.SC,C8*?*5PR-9Y9UL1!I(4D0"F>*Y.&2-4I^?RB\_L
M-C"7;DI;.T.M/8]I+:2YOY>S2[4]B&^6>(.HD9,TJ'C>LL@9V&_^F ).C,PM
MTU^T,C2;E7XDIY  N1/U5Y/?BG5WVX($5U9\8DXS>K@]YFQ(3I@AU/Q,'&MQ
M<^0]^#6/O ,?RCR?&KG,2:%3R %I\(-TT#N )_'HD/DS<,:V"3A:X OX*_(B
MGD06<Z<!. +$&KD542EB:+O DP]YIT)%TKD@%Y%U0^B3[]PI-7!Y"_ Z!RY\
M#RS*CO5C@/'A;FU+]9@CI1VBCVVL7-D"_W$K8!)6HJL>V=@<? 4Z*0O<D:AM
MB7.S6Z*'\G:!M"2_)[;%P8KQ 7&\UO<9RTP8$Z[.#B-4+<PO8##$H8BB$&O-
M^?+&=F :<V*P2@8N2^ HB81^5?M<H>DM,4^W7.Z%GSMDD/)[:@74G2F1P 6$
M=,GYPQHA!.Q;C'X9? TQQB;(AF^9*9"J\*S>S/0<? \:SB]XNB,SZ#OC;>PQ
M=+H.QT \- ,.4+G=/P0\+%N!*>@NVH>!F!C+C!B @%(ZQ/#>T" TS"0H#OUL
M1E 5&MUO-QO BL((6JB-RK+ &A+29Q9$!U/.5<PB,FD6 ;94)6-J+)L;QJDA
M'HH33WCXFJ@9*=4TL)V33C__Z;QST0^-WV43F8)Y<@>,#4X*VT:3(/LLH/,W
M.;[4$=1'H)$ME=&@)7\/*/H:2!,\"-L N[9A;D=@.<"3,+<XEYF$CI$4'5.*
M@C"J?QA9ILI_+#:$-'$"U&/7*"=T)Z)/3.D?ZBZGRN 0?8<11AR2G<(NX!6.
MDZ!D[P43,7.1Q(0#ZO5"\(B_]T(Q#IA_QYA\T+^SL<X?.%@Z($KVX+8,@TMX
M:LZ$[6'M_Y8;(#HEDC$?C6-D(^^*=.@GY"L7:]$Y.V^A.5%W8$]GI@ =G4Y[
M.V9B\Y,L:89%?@?#BL&0<YD"_/9 1")C"-02>X1EA%.P/A/2E0C&"L@*D6Z.
M6#M*:_W,81BVVV$\[_M8(@UG,T="O'JY'J^FP95YU%@/5S+O #?+-])!)^CC
M6A9%;\<I.8*_.<VW<9/;O1UB%60?$IV< &/H]6\I-]'U %!QL08(N(O)-:\%
ML"^D5 ("35GW0$:K._6=\'K&P/?+X7J9#XWGJ8UPAP'D$VP.?0RT(=M!H8@B
M",,5+G %JJ#B^>I0(+)VPV:(H<(DD.H^F*THI0C7AMD#!Z%P5_CMS.ILZ==4
MT\<L091??PGB/V_QX<6F;] \M-T[ZAKY8]N^05\O7E> RNT]:U'J%5<(+A\H
M,ZO:L1<5>Y4$3"4!+Y) 6 &>4(,EEK!%D(>,"4 4Q$\W=M0SA&?G+D>,$J^>
M'L,/=8[T A5P,J\/-VK"NV&M-QI<> =_YJ#GD& <? P":\BG;%Q<%]51&K$!
MZ28'U^1%SEA=9U,'H-;29<3.B*K\Y2?D\=BERW?<-,-K&75M0F>+S612%%T%
MZ7@ _DSJAM5?%%/([FK98R48-RW E%M@07@M\HJZFMP;R[X#CSYBN0S"QXDC
MMOGG0!6,D0A:B+<D_^H$P'Q]1[EUA[EB54%@.5>^!!6H:YF8R0&FFH].0@'/
ML\"%KH=RDT4FK%POS"7"*MN2\0J>GI$1 FW+GD-?5<O'9Q-=H^2%CC%5QP?D
MZ*)L1)06Q""0'=F !V7C <M0?8SD&C)SG]E!F*["\^(M=RH&Z3[ 2 Q<@8GO
M9Q1-),"-#LN!^JE,'X=)K+W((\^K)K&0Z2\(0B[I8,0.9/S#90K,#GP!TG-)
M#5"3M2>&B07>T,H6*R"A8LS#-DC-"'0_HX,0N"'"^WQ5*:K%B'JEP@1O5FF,
M .B8QXS$FT3@/@XE\RY!%*(%NK+""G<S<X 5>TN"-8O5*E35<"T1*FL+B]MS
MFL))%).UDA*QH+4!)4F^L1&D;^J=9%[H#0\[K6C1"LF5J!/0CXV="#JQHJV+
M'M5.1!D0%-'S@FXF7NM55(@.X)) 9?.*-KZ\>#9GST=EC2P 7:9X%9QXQXLZ
MT0\Y5,JPZO9"1YFY&LD+;Z2\!0H/(6+LDSS)$IE*-[U5NJHTD\PULX Q"N8M
MK+_+)6?AU#+AFP>X=R.%$8"_<-$.YW!2VJY.<7?7@EG#+"F;CAFR\L>1(:_U
MQXAU,W<,) LA1Y+AXD*'4$H[E<-!@"4>3Z3%,/<@)S-'G'"A'8E9\6#+LI#X
MA=A=TO E#F!%<B8]%#*^#9K(1=4.Q$=\ PFIE$2II)J++6+BER"04A6C+H!^
M@INT,#$*(]6\U&ZH-T@OSAT1Z\)RN=/.#%CXMTB%%]9*L;=H/73^$C\,+>:Z
ML(<^<;Y,*JHCX?MS803NBK*SR_R93*NX!ZXM$,4!L#9PIEQG!?(W>'OL2-V:
M;_QS &@SE$N 4V!RJM:Y!'-KYEZN=G@.H&=H;HI]P4HVAGR1>.:!U?WD@@_N
M283(-W^U1BZ,U8IQ [>O4#X1E,6;X>Y%!\?,J4V(1&Q4E/$0&H>6LIX;N1-Z
MP*2QP".X@!;;8) +#5\"@L1Z_.^Z]?AQJ].-@E:"W"7<UMF/::;0:+'5XEE7
MK'_BDCQ^ 2!DZ??GYE) 4LD-8"K/CS8KH2^8;X?!(@T6(86EK#?:5Q3*1F?!
M5YZ'7-A=^K0C:9++@0W1]#'?7@OW'YW:A<4CS1OVM.:$T88]=>;8X4</Z#V=
MAU]!$#_X:8&G']O](W5O-27RLW+^I+S3*#5*1NF*31N-?*DP]F%<W,*V7Z1+
M1^,W'W_]D=*-^ZLWGL3/N=C&<R&W\>0$5C 6]F\6YOR^QORLCJY/D_@SB7D]
M63]',"6M^LM)I2U6&45-5>S;HC*_$\OZ^'YLLH5)@($) :)R5:'HB4_L9O ;
MNQ&XWRZD'Q'\O3' PP7YRG_/!#QS6?[UISO^;3NX0#%5^>4_)/>PS-1%;N'K
MX/&-.I4:M[*);WC)LVW? TB!$QGZ@]NO4P[%&0$6CS #-"00EF_&5#56#R@3
MBYCBNS4#-J;F,*.6,D5A037 +?H![IX6W4'"/;9=?L^,9\;.BT)9@9U_SBM(
M'ORHT.+Q^<0'ALIKSJ0_]&V:HU;OE%R^ZUZTSKN?+GOM?H[T3MN%]&]0_"B9
MRS'Y,3VN(#\2K_A0%GZC#-S2R<)'RD(B'NKBCX=$=3#;2[S38/7K10;K/CP:
M'[3Z\*A%KTB.F,6 +_WFF>9CQ5C%19BR@1Z])HE-N4NS&[U^7.W3),NZ]7PO
ME_H)Z_[5-^1,KL?MD6-\[? O@CI>9VG^,1^(KQ]<1:LML>_*L_?3PVM#^S"Z
M:7T<?RNVC.EU^>SF>^5=_?K8:7^8=7N6;7@WCFE=O/MVS>XO_K+]+[7/]M$!
M/])W:_?C _[^^$M)XQ]G7S]_VVVW:;#SN54=3Z?>;,+]G8O=X\'TKX/;:\OP
MW_5OK_^ZU=^]#SY^:YQ,Z\=G7S^W=\LE[8(>'YT<'[[OV1-]-!B?.+4/LU:5
M[YSWN_==[2M]/_WROC^^_'CR[9.G4>NOCG9C'5X<C[\[E:^5ST>^XYQT3KO5
M=V<?SV>==E__<'%T^_=H>.CWM*Y^9%O:@3?YME,R=DJ#\<[?UW]_+O$:N_4^
MGM<K?[5ZO>FG[Q^E1(H#VYCA3T@GS>;_ 5!+ P04    " !H1G)<7'SN "P6
M  !W6   %0   '1M,C8Y,3DQ9#%?97@Y.2TQ+FAT;>U<76_;2+)]%Z#_T#</
M00Q0_MI,9I)XC9$M.W&NDQBQLWOGZ:)%MJ2.23:'35I1?OT]5=U-4I9L)UC/
MA0+, K..);(_JJI/59VJ]L';J_?GA_W>P=N3X0@_!?WOX.KLZOSD\&#'_<2W
M._[K@Z./HS_$Y=4?YR?_?#(Q>?5*[.T6E;C2F;+B@YJ+3R:3>>0^B,2E*O7D
M"5[$JQ?AO4I]K08RU=/\E2CU=%:]%IDLIQJ_[CXY/#@Z//DZTV-=B9<OM_<.
M=HZPD(M;0W2>?YJ/;?'ZWD<.SMZ_$9>?CC%UMO_BY=[+O63O?]77ER\'>SJ;
M[N[N;7\IID_$\/SJGT^^:\"['O$2>?Z01#H;QJ.[KT57)+'**U6R(-Y(G8NK
MF2IEH>I*QU9<E,KB>RN&2:(K;7*9BN-4YSJ6:;\G\T0<:<Q77JM2C&0EQ:0T
MF;B82:O$WKAY5%Q6=;(09B+>7 UV]_=_^U70NQ@]#D^T;W\P-PJSS%3F7L4.
ME'4BD)48CG8N1F)_=__%>E5]KY7<DLF#0O[1 >\0\MEA1Y+C1G82ORZLMJ)4
M-TJF5LQ@J*KL]XXO3T6*S_ 1I#?Z>#$4B8IE.39?%RE)^=EH="R>YHFTL]<8
M1JA,T2JF E)JQM\2D-P8CT/:2LQU-1,24R5U3"L1$Y.F9DXOO=P5B5SP7(FQ
M] D]W.\U:H.!Z#S1-SJI:9D\%*VU'9U6/$WKV-A%:HL9QJ"!U,'.V4^NK?>C
MR\'GB]&G2X@(MIJHS.2V*F6E1(Q9=5ZKI-]+ZE*.=:JK!<D<PA1[O^PN6WZ2
MP>;Y30S\D\K%'=(X'%++AS02,R43LH)$C+'_Y$;F,0DEQ<<L@.<O?GL1";9S
M"4"8F%*<?1@-5"['*5F;!4Y@(/ZBFBE1X;DJP[0DP0O8LLZMR9^6]L_:O+8B
MT5;1(2 P,7B^%+FJ2Y.:*:\*7YLR4:7=;"%#H*<?/UQU1QE,9*;3Q:N'QN%G
MK?ZFW+2,XD<G5V]/+D?#J-][/XK$>UG&,[?BO=^B#G+2G(=B,! KL!^YQ\_R
M>%L\^R!M(O]\)=X,/_S/EGCV-$U(]O3.TY+_&0FO+/_5L<D*F2_\MUM8AA0!
MY@>VDE-%P%2I>):3IA8X/?R"("LA(Z"QH+H8)E8N6+<)(: I@B'0 SGL4DQ5
MKMPQHH\E4,S"0'4L;(9?1&92%=>IHA>P.;+0?J\R="AEGIN:C),'*YR;:T?"
M_Y<PH*7/:2$%3R""'WJ*0YRHURQ4<4:'(Y?!2YI\HDJ%*03>':;?9@J:*X/I
M.N>Y:M&CCD5_4BG )8'V.S8]"C8=B;$B:<U4FBPI^=?!_I[3<T1P?6P*E<\@
M=1C/2.7D$+9)V[S#?F]YZW7E3F\.@VM<,ZVE=55)XZA)<HVK;YZV*ZY^4I=\
M-FU=%*:L:-'^X XRD^C) I]@(3 )H"A&P*+'.,U")]H4LII!G[2$-T?#O;LQ
MP.W)VQY,P9J@/6Q'!L6Y#=(*BD[L05MRPJ-]^5##_0!,PTD"T]-T 7 ';.L\
MKMQWM]#/?6@F_OW6&-D;QC"&<0E7F+#7?G.,'UNPT*2&D@VI<XZ-PB^7Z@%P
M]"LUB Y^ "*?78RV_,H> ,OMC4;*HT,7 7ZD\WG1,=[-#@>?'(8CMP0JD2";
MKU*5>,SU&#K,Q4<<V\&Y',/-AD/6[ZW&T3@L=Z)(Y#%8S"4, >$9 !6GP>1P
M&8A:X**K]LPT+Q_/M)J(]RIAL_@XF6C8;B3> =:L> O@5 #QA+S+]F@[PN+P
MPX7O0! K)ZI:1*("](9 *&K1 ](A\VO!(C8EN?L )^0*4D5'%IORQVPO0+Y#
M%H\B2S'7LGMH@0<GZ *+^^C>WWLI"HRJ8XW](J>9STQG0A_O.GF&J2.Q]P)1
MCH'X*]-,20_1@ :Q+;T#0"$HRRE2AEM2N24P?=:.L[\5K4-!/KX=0747ORV&
M3JCO3:X!$/0\-)7IJE)*9$KQ")BF _V_!-C'0N.T3D@VU0S.JB.]F:GA+YJ=
M4  /4!0$FO%,YE.UV>=_:.G\W&A3VW3107AHY)W,:UDNO,2#^Z,X8%GKG- H
M)%7L7)N\I<VRUF0O .RTOBQF6S1D@/)"DZ.?I+5.Q#.D/5"R>XI2M)(.8 )M
MCW%:V*]AO7)"3JA-LJ">!KTYE6JU?Q(6Z(:,.&&S=>HLG+R'2!9V@AC&X0@@
M @&!RDG#\YRL%8Z*%\':E]-IJ::=4*F826$7>1VGB")<-$+O  IT*6!E!E:?
M)Z7V_A_9J;'0#_;KIR1)L /)-]MBFJ'^"Z'NJ4:T] HG?(JH[5+]65. AF$1
M!GLVZF!T]J]E"F90F0*/[!<-<31 >%*9[)5X09^-V6TVGQVE,KX6>YC<FE0G
M6, JI4.1>KO1@QW,N6;Z,=1W/1@KP!C66/":NTMZL69%M,P?G;(CF!V2C!/&
M9FISR">T&^[N!M#S7@* O73>58X8)W40T0'M?J]%;=& -O#^.8Y2LNH7R)=,
MX$ %OV'%LY%+[;>V.\2 =V>ERB2'T3CZ8Z0?E,@P#;#,K6Q3_)+J##!24G!)
M:/\,@/%%Q14=QC]KZ7@$:Q& PE"W "=3(#1VQ;"^@FOB/ECSV$0IP>5IZSYI
MIC'RJ(FNL+=2L<L@49'3XT%3,W]PO"BP2HCGF[QG(EYL_XK06]/ZO/AMG;$&
M&YFU7O+L3/BDJ/G@K-_S,AVK:D[PQCYS;L2T-'5A*1/SBMAH$&III'01W4VB
MM<(E%7D!=ZB[B*B4!\C K8[W64OLW>ERB$ED:L86 '5-EDM6#TN!_7*X@<E-
M@IRLWX-*C:!_9F047K?CDI@$SI,AA8*2[A0^HKR!MX:S03J4\;>8I#%4_RKM
M%VLKE,&Q<PM;#6L#S9GJ:P5OFM1DK.TR(/'8NZ2N;]QHPWB#DP<XBZ\C3F9T
M0GHA&1V??.1#ML+-$#1E+N@Q++M^SP4&^,I*RJ6CP,3\6W$ZB<-H "!3Q\J1
MM*'&](84VJ;UB*D2/K5>(=^3V*_+/3A)]F$'++<!K/8E@!=DH)H(.):U16!R
MP[00$T*4R")L/ZIUFO@H%QOH!GZEHA@:&VI)[!5$(B##9+)E<!EA*3["IQ!C
M61+!0N\&<&E/SFV8B]9^AQ/C$AK$3250/E,>Z6Z[! 18UII8L\FS==]U"D/*
M]K;#*C<*/<MHVX![0I$'W0XS9T1'T[]C!*S6,0;DCB@L=@HM3%%[,;CPM.NH
M[EAE("OF2MQH6#IB3RH]>#MCKD)/<T?EL!(@'<2?UI*6NZP#6PO'3XZ_J4PE
M0R;$-"!I+,C!DJL*Z1_3=@UE=,LJ?YP^<A$P]C,S!>=Z)E?,WMN9GE2WN&CX
M79GH*<!LCB<X>;6+K$  !CG&@IRZF@@?4H?CP%07]LR0Y+6\R<AT.]]?SPO<
M@5%X Y:.([B,1%Z3?/*-]TZ09J55)T)HD&==@.:-EK&%W,C7 L&2"V)"R$;C
M7*H"SF:LRC8;=!I.C;DFKS:7);_D,TB.\'R"SC9'T!73LDAGM&X?U%#DA<AC
MRDDS^SR92A_LT*\+)<N?0;L'1X<'GSV5=N&XT64R[?/AST"H.5HW$IY#"SCI
MJE/#EH)U"?/[#MLZ\G%JU>^=!O:I4ZZF-*A%NU".NKJ?:UU'N[44Q?VT6[_W
MEHID&/<37J#\1@QS29F.ECAA)7S'X!@'1GXS@7.[XC+(/&):D=B%&ZE30OO(
M1V(%@HL*F4-UNU#71E(N)@BEN? Y46I-==-V<):SH+JJZ2PW['G+OD7D"4(D
MP2-C]Y!WPSM<JX7W\JZR -=] ^^L?$)#&.$H"(X,^[V[Z?X-MTQ8VX1B_'Q*
M7@O13H?Z"X71MIP%),N7"JI(>YRB*D-(95V@Q!)W?F7)^W$&%_3 83_QGIVJ
M**W$>1YB/6'V@4%"UD<H%R\(3"'YE!Y3R49+]WL(G?V_"9V?A-#QB/V1XWM3
MP.B1'2R >U,%L,M#A34IZVFG*%P QB'%C&C/?F]!>Z6J)9\A9]J=^EM;9',H
M,Y.(0GWI&&]AVDS;=37!]<653D"'-&!;(+:AJ*+?ZX0532RQ4KC&B[Q,BI':
MTJ((E46.8DR=)]852AJ6)E%%:A9AH-OB(>HVX6AEX;HMNDE6I]B7J% ROW'Y
M04F0ZW=D&\=EI4[$.T.QG[B2B]24WN>0%G,->/D7@K].QMIU6Y P182;C2&/
MUG QA),:G8;PSY>9.Y7G;L<:@6SCI'WV+BX9@)TVKMJF"*N:M'9=D6ZNQAQ,
M2$^5(9B;555A7^WL3"'\JA.-;\.D=JR;98!9!FWKQ8Y;KW7A'C>$;+;:C@Z'
M8XJ\0VBVZ3'J2FKD%<B]+@[48JA$ VT0M;4!I^9L*&XZ+;LX\H.]453X=]D[
MWFO*?2X=SFH7[K<-(11&^OXTJA7[2'+01)((3)9;:S2G_AVT5?DWP%0+N@YS
M71RH7"#3E)"\<;?%)?_R/1T3CG@8*Q@UT2I ;J21!/Z>AG&Q8U)S$A_VU^26
MO&N"P(A_S;!HYM.P%OJ4LG<YSN%8&N9]B;2Y&'&SDP-40/"@="TZD$I%](:8
M(*(U&]Y"<98O.3KGQASGUII@4%CBW2DKAMF-IN1(O&-24YQ_\DFX_4<=59(^
MENN(1,8P[$1-.1(O/^5:Y.M!4XR,G*O2^2256=;V7CEFEQ,.#,2IQAQ.D*@U
MB@=@E^Z1"?"5CT5*S=Y4U8;RGWV8G&]YYHYJJ2WQB8W?<HUT'B D^BBO.O)A
M5HDL:."#ZP[#!-EUNF0I\6OJL!!,7(=8V]$<F:DXD?+'@,8":COBEUA.FI?I
MK^7PH3N$8SN^XB0@G-$4V]B:G"_.!!$V7%XBIP$)<<.5#V=<!.+V%'5Z6.D9
MN=J6)12RY'BIJR(*G*YH6@N6<0SVMN 8R[&-2VF*)<('6X=M%;[SSA.##@U^
MSGSOD^/?'1,H X&UGC"?*9E6LX6X,6F-" '.M]M)#"29R!OC.%O72^-YQ&X[
MC;=V+A-\N"02S-B:P-6C'(3ZQ=-BK>M!J)=/E:.K76R(0ST%B+7TKLR;I@&J
M\(1(VB7I6 B6.?6%00"(TEQ":/N:J\9A,4-/%1Z,G.#QS0;$;FDBKDLBA; !
MUUV)/:1U*%3)-561BJ"-8_\?<<K?Y8^1#&64"ZD\X1IJ<)<\9:#@F_)VMQ@,
M3&2^'U'D#;6$Z,H9Q[ F,TNUY @#YS%LSY5FU]O;<O,ZEPBJ6:F:2GA[5X I
MIWL*>$UMR.V/;(A%[2I:Y$D:^;JST]*^%&#,[7+%N]N1Y2@0EGYPUDMM8'5!
MCTA78.CWL.:]?;^!C;;-[R$[_O$WV?&3D!UGN69/6'8=QOIJ*Q_R[S]12TZ$
M+VJLJ;VOP'ZT= V(SM"M-H_&H2A;J%A/- 9OX&A-GUR_%QKE5NJBSNTSIGR3
MH8'L=@USH\^BN_/@D9P3.(Y>9'8_3]1TYDEBA]C%U\P,-WRPDB50D+I"*KL4
M\[%]$%2^!]1+E8IWV^+4?,5_&$'ZNUOEFKD;,N;9^W>GIUN.7""R0:<W"#DJ
M[OE[<!0'HT?#)M:FGXW-GB!HAD)+.]@77]@@@CCXO=@,PCZ77BD4PHS/.<WZ
MUI3ZF\%*]G?W=^E0> ()BSW+<\0TVD)^H59Q.<>O_,6-6_1P2LSU1IO,HU[L
M8>H#6<8]UW4Z-WLV=1=!QAN_T,X2[[TAI;F;Y#^ZX+32PG[[=E.'7VGN,FV+
M54"ZBU&Z/[3UP6NW&_D_B5[O#96WVS41, :BO'O[ATP<N6Q[62I,S DK/^:6
M<*[FV(Q)^.HAH<;*-:OV=A"KD&;,X'DU>50")QM#KEP#: D1"="I.OQYO]>2
M&ES,G*KVLDPD,@6GAE@I;FET7@O'3Z*JLTWG@Y:LJ,XUPDHA"V"YY/2"4E%[
MRV3)0ET1HS7,%6;P=MD%9AE8)3(>C%;6!3L-<D<-&[(M1ESJX(2B<C>AT_8R
MZ4KI(Y2"(J=BS<E/K%+E68U;E2-239VG)K[FFQM<,5JE/9J#X*ZB(E.G#QQM
M7W*/J\8>*T2R _ZF-0C*H-,Z<1W&*R67UD2X\!(XQ_9MKMGF,>/&1EO-HT+M
MJ:N<#<Z-N6;)75+_$,O_)W 4/Z-'NYIQIV_*>$Y9-,Z.#>TSOI Y2)TZ7#<7
M:R,4"#,</5'4I:V)XD'B$/@#0&R)E)).]8VV3+T[UJ+?NR@UM?QB@?!$KNGC
M'#_\I91/BNNY0T<V[KU\^0N3!%9U9N?^D&I1>(J)0%LEKL]D;JA+PE.@81]C
M:L2[Z=0U_>>N:ZSYN.E2HWLZ1"Y4JZ\@O$7>L_+Q7*?I[<\RN;C]D;MUU7Q*
MF9"&%F5)W)VG/^UVO^<;1^X4/S0V28F/A<)]"M<@MW?OXCHW\U0E3/596V<%
M%T B\:5.IEGH+G82\+418N)+%ZAS:T^_5ZB2M.$:VZ@WF";?AGLE?S^==:87
M0<8M&WQK;%ZPX\]8/;?426RCR5W7$MY>B"GWB)KVUH._P\8O+XU-PF=#"_0/
MM_3&E0A%)T=53HUKLL?#8V(S9[3>Q#GIA:G#E3CZ;LX&QIU(<55W$O68'J%D
MFYK&L'WR>&R#/K4Q[2EJ>]KOUN.VN*3=W*-HYT6HDZMV;5&YH8)&IIDCKDRT
M;!5>@:_650W6E8^#L;3M7) C\0!M\-CQ9,M_M24TB[VFRXYKS:ASDS.4-RJZ
MYC*EY91KR?*5/G-RNYUZ:+,4BJ.7NT$!)/<OI9W;MYIZTK2IIC[>*I:GHZ=L
M/<ZT.^ !)T]'P[:*B*6Z*"E$LBPNNJX?AU]6!_57-+HW9[N#4F7NOE%?WQK2
MZXLYV& U-(V3ROZR4,*?YPAB>;VN(:U-E5S;;3."OVED[S+,53.,'K)#HD1(
MAVW/C8U+770+S*6VU_Y/+M ??2CIG+9=A[&[$BMK5^SHGGONW^8SWSGH'K.;
M@WXO9"]Q)WX=[MZ!:X)>)X1Q35R:9?K-!8\I%7W85P-0B8!?_R($D85K<8/_
M;CH%J"F9:#NL> 27V?9%_V,O8O+E>=1I%ISHE-L6V<>[NPK$')T<DP-([P,M
MOFSBA -HY.MKS!@Z,>F2+[N75&/@'EC*267-=S/H_AL03L?(U/X )G.SN/N.
M^[HXQD"D'W/:5BONL9?^CVN0J=ZG %<HL862UWB<<HG&_+A>&5HP?3@$/_QO
MY9K$X(;,./4A2A0\I]\?9X]29SQ_]S$LM2Y<_DTW5BS[T.";^.') _Z!UJS<
M21XK9YA,"LPA2G;,;B(/W<X]-Z=_KC>\7/H]-8WG?]<T?I*:!O**L_R&\WK[
MBC*,O[Z)JL.^/?Y-S4("+-_)+*L??>R1)@@P9;-^)S;WAWXX0N#[K_68V*3F
MP\?7V.=#^84V^/NZ5D'7"[BYZ'&N)^HRUF*8W!!K@B3R_/C1)SF>U8","YG(
M5#[ZX.\I>R+ #_;P5V@XIAW\#@>,:$A++ZN?0;_ $[IC)O\:+/E46VOXBGFN
M_B+;>3S*Y@.%S^_,C$AXAH:35!LQS+@KTFPTV?3Y$/'^]A>W]M]+DGKAA9ZF
M<6N'C[Z%SX>(#,VV]$*Z9^I'F_/9KR]VM\1OSU\,7N[_\N+_X6QU_];L=\12
MO[P6'QT+]$J<2UMM3FCU<)SS'7\%=YTT=N@/![N_)$Q_</C_ %!+ 0(4 Q0
M   ( &A&<ES?6QK5,0,  /H+   1              "  0    !G86YX+3(P
M,C8P,S$X+GAS9%!+ 0(4 Q0    ( &A&<EQATG?\_0H  '^&   5
M      "  6 #  !G86YX+3(P,C8P,S$X7VQA8BYX;6Q02P$"% ,4    " !H
M1G)<:*:7+6$'  #D5P  %0              @ &0#@  9V%N>"TR,#(V,#,Q
M.%]P<F4N>&UL4$L! A0#%     @ :$9R7%'-BLLY'   *H4  !$
M     ( !)!8  '1M,C8Y,3DQ9#%?.&LN:'1M4$L! A0#%     @ :$9R7%Q\
M[@ L%@  =U@  !4              ( !C#(  '1M,C8Y,3DQ9#%?97@Y.2TQ
:+FAT;5!+!08     !0 % $<!  #K2      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm269191d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ganx-20260318.xsd" xlink:type="simple"/>
    <context id="AsOf2026-03-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-03-18" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-03-18" id="Fact000004">0001819411</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-03-18" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-03-18" id="Fact000010">2026-03-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-03-18" id="Fact000011">Gain Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-03-18" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-03-18" id="Fact000013">001-40237</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-03-18" id="Fact000014">85-1726410</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-03-18" id="Fact000015">4800 Montgomery Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-03-18" id="Fact000016">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-03-18" id="Fact000017">Bethesda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-03-18" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-03-18" id="Fact000019">20814</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-03-18" id="Fact000020">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-03-18" id="Fact000021">500-1556</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-03-18" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-03-18" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-03-18" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-03-18" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-03-18" id="Fact000026">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-03-18" id="Fact000027">GANX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-03-18" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-03-18" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-03-18" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
